SEP 4, 2026 · JOURNAL ARTICLE
Increased risk of Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors in lung cancer: a nationwide retrospective cohort study
Respiratory Research
Rigorous nationwide retrospective cohort study with propensity score matching, large sample size, and consistent effect across multiple analytical approaches and subgroups, establishing a clinically significant increased risk of PJP with ICIs in lung cancer.
Reported
PJP events in chemotherapy group27
PJP events in ICI group66
Incidence rate, chemotherapy3.35 per 1,000 person-years